SEATTLE and RICHMOND, BRITISH COLUMBIA - In a move that underscores the growing integration of artificial intelligence in life science research, Monod Bio and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement. The deal allows SignalChem Biotech to incorporate Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies into its custom luminescent assay development and protein-fusion services for third-party customers.
This collaboration is strategically significant as it expands SignalChem's specialized contract research organization (CRO) capabilities and aligns with Sino Biological's broader strategy of embedding AI-enabled technologies across its global portfolio of life science tools and services. By leveraging Monod Bio's AI-designed proteins, the partnership aims to accelerate the discovery of high-quality candidates for researchers.
Dr. Rob Burgess, Chief Business Officer of Sino Biological, highlighted the practical benefits: "By incorporating Monod Bio's AI-designed protein technologies into SignalChem's custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly." He added that the agreement strengthens their ability to address complex biological questions and advance research programs more efficiently.
Monod Bio's LuxSit is an AI-designed luciferase engineered for robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance target recognition. Together, these technologies offer versatile tools for developing customized assays and discovery workflows, potentially reducing development times and improving assay sensitivity.
Daniel Silva Manzano, PhD, CEO of Monod Bio, emphasized the expanded reach: "SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base." He noted that this partnership reinforces the value of Monod Bio's Monod Inside model, which integrates AI-designed proteins into commercial products and services.
The non-exclusive nature of the agreement allows SignalChem to use the technologies while permitting Monod Bio to license them to other partners, potentially broadening the adoption of these innovative tools across the industry. This could spur further innovation in assay development and protein engineering.
For Sino Biological, this move is part of a larger trend of incorporating AI into life science tools, reflecting a growing recognition of AI's potential to revolutionize drug discovery and diagnostics. The company, with facilities across Asia, North America, and Europe, is positioning itself at the forefront of this technological shift. However, the company noted that the revenue from this business is not expected to have a material impact on its overall financial performance, indicating a strategic rather than immediate financial motive.
Monod Bio, based in Seattle, specializes in AI-powered de novo protein design, creating novel binders, biosensors, and other functional proteins for research and diagnostic applications. Its Monod Inside model has been instrumental in partnering with life science companies to integrate its technologies into next-generation products.
This collaboration is a testament to the increasing convergence of AI and biotechnology, promising to deliver more efficient and precise tools for scientific discovery. As the life science industry continues to embrace AI, partnerships like this are likely to become more common, driving innovation and improving outcomes in research and medicine.
